Anti-CCR9 CAR T Cells for T Cell Leukaemia/Lymphoma

The goal of this clinical trial is to learn if anti-CCR9 CAR T cells (which will be made using the patient's own blood cells) are safe and which dose should be used in children and adults with T cell leukaemia and lymphoma. Participants will: * have T cells collected from their blood and these T cells will be used to make the CAR-T cells in a specialized laboratory. * be admitted at the hospital a week before the CAR T cells infusion to receive a short course of chemotherapy drugs which prepare the body to receive the CAR T cells. * be given the CAR T cells into their vein. * stay in the hos

Trial Details

NCT ID
NCT07300683
Phase
PHASE1
Sponsor
University College, London
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • CARCCR9 T cells
Locations (sample)
  • London, United Kingdom|51.50853,-0.12574

Key Eligibility Criteria

  • Relapsed or refractory T-ALL/T-LBL following at least one (≥18 years old) or two (\<18 years old) standard prior lines of combination cytotoxic the…
  • CCR9-positive disease as assessed by flow cytometry
  • T-LBL patients only: Patients must have measurable disease
  • Agreement to have a pregnancy test, use adequate contraception (if applicable)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →